Blog

Bringing a new healthcare product to market requires more than just clinical success. It requires coordinated evidence generation, regulatory alignment, and stakeholder communication across multiple healthcare systems. The global value dossier (GVD) is the primary instrument for this, acting as the definitive evidence base for market access.

However, manually synthesising clinical evidence into a cohesive GVD can be time- and resource-intensive. AuroraPrime’s GenAI-powered automation is rewriting the process, making GVD authoring convenient while remaining compliant with global standards.

What is a Global Value Dossier?

A global value dossier is a comprehensive, evidence-based document that consolidates critical information about a pharmaceutical or medical device product. It serves as a structured guidebook that brings all the relevant details together in one place, covering:

• Clinical trial outcomes, economic analyses, regulatory approvals, and patient-reported data

• A product's value proposition that’s presented to healthcare stakeholders, including payers, health technology assessment (HTA) bodies, formulary committees, and prescribers

• Efficacy, safety, and economic benefits communicated in a format that supports reimbursement decisions and market access negotiations

However, producing a rigorous value dossier requires assembling and synthesizing evidence across multiple components, each of which must contribute to a coherent, compelling story. When this process is inconsistent, or the dossier falls out of date, the consequences are tangible:

• Payers and HTA bodies may reject or delay reimbursement decisions

• Market entry timelines can slip

• The product's value proposition loses credibility precisely when it needs to be most persuasive

Key Components of a Global Value Dossier

For teams managing clinical documentation across the R&D lifecycle, including documents such as a clinical trial lay summary, integrating these components into a unified, submission-ready value dossier requires both rigor and efficiency:

1. Clinical and Economic Data

Clinical and economic data form the quantitative backbone of any global value dossier:

• Clinical Data: Results from clinical trials, including key endpoints and outcome measures, establish a product's efficacy and safety profile across patient populations.

• Economic Data: Cost-effectiveness analyses compare the product against existing treatments, while budget impact models reflect real-world payer perspectives.

• Communicating Value: Visual aids such as graphs, tables, and figures present findings clearly for diverse stakeholder audiences. Also, long-term value projections further demonstrate sustained benefit beyond trial observation periods.

2. Patient-Reported Outcomes (PROs)

Increasingly important in healthcare decision-making, patient-reported outcomes in value dossiers capture how a treatment affects quality of life, symptom burden, and satisfaction. Moreover, it captures patient perspectives on:

• Quality of Life: PRO instruments measure how well patients can perform daily activities and maintain their overall wellbeing during treatment.

• Symptoms: Standardized assessments quantify the degree to which patients experience and cope with disease-related symptoms.

• Treatment Satisfaction: PRO data captures patient-reported satisfaction with therapy, offering insight into real-world adherence patterns that clinical endpoints alone cannot reflect.

3. Regulatory Information

Regulatory information establishes a product's compliance foundation within the global value dossier, providing healthcare stakeholders with confidence in its approval status and safety profile. It also includes the following details:

• Regulatory Approvals: Documentation of approvals from relevant authorities, such as the FDA or EMA, confirms the product's legal status and the scope of its approved indications.

• Labeling Details: Approved labeling provides indication-specific language that underpins the clinical claims made throughout the dossier.

• Post-marketing Commitments: Surveillance requirements and post-approval study obligations demonstrate ongoing safety monitoring.

4. Real-World Evidence (RWE)

Real-world evidence in value dossiers draws from post-market studies, patient registries, and electronic health records. These details demonstrate how a product performs outside the controlled conditions of a clinical trial:

• Post-market and Registry Data: Studies conducted after approval, along with structured patient registries, provide longitudinal evidence of treatment outcomes in routine clinical practice.

• Real-world Performance: This evidence demonstrates how the product performs across heterogeneous patient populations in everyday clinical settings, beyond the protocol-defined trial cohorts.

• Outcomes Beyond Trial Conditions: RWE provides insights into safety signals, adherence, treatment patterns, and long-term outcomes, strengthening the overall value proposition for diverse payer audiences.

How AuroraPrime Supports Global Value Dossiers with GenAI Automation

Global value dossiers require structured, compliant, and data-driven documentation across multiple evidence domains. Creating and maintaining them manually can also be resource-intensive, particularly when updates are triggered by new data, regulatory changes, or regional adaptations.

AuroraPrime addresses this through medical writing automation, coordinating drafting, template management, data summaries, and quality assurance for end-to-end GVD lifecycle management.

1. Automated Batch Content Creation

AuroraPrime automates content generation, data extraction, and the structural assembly of global value dossier sections. The platform also reuses content from existing regulatory documents and auto-generates new drafts from historical and structured data sources, reducing the time required for initial content creation.

What’s more, teams can apply a standardized global value dossier template across projects, ensuring consistency while accelerating batch production at scale.

2. Automated Data Summary and Updates

Keeping a value dossier up to date as new data emerges is one of the most labor-intensive tasks in GVD management.

AuroraPrime syncs Tables, Figures, and Listings (TFL) data with document placeholders and automatically generates summaries, reducing manual effort and maintaining regulatory alignment throughout the document lifecycle.

3. Built-in GenAI Quality Assurance

As an enterprise medical content authoring platform, AuroraPrime incorporates built-in GenAI quality assurance to ensure every document meets defined standards before submission. The platform extracts exemplary historical documents to establish 'golden' benchmarks, then compares generated content against those standards.

You can also tailor evaluation metrics for each document type and generate visualized quality results. Moreover, QC thresholds are fully adjustable, giving your team control over compliance parameters.

4. Automated Drafting and Updates

AuroraPrime monitors document versions and storage locations across the authoring workflow. When upstream documents are finalized, the platform automatically triggers first-draft generation, enabling early drafting at the start of a study and rapid final updates when source data changes.

For teams focused on automating document authoring for regulatory dossier submissions, this capability extends naturally to global value dossier workflows. Consequently, you can reduce turnaround time on version-controlled content across multiple markets.

Use AuroraPrime for Content Authoring of GVDs

AuroraPrime enables efficient, accurate, and compliant global value dossier authoring for pharmaceutical and medical device companies with complex market access documentation needs. With its GenAI-driven automation, flexible templates, and built-in quality assurance, it’s ideal for organizations managing multi-jurisdictional submissions under tight timelines.

Organizations looking for pharma R&D authoring solutions will also find that AuroraPrime's modular architecture supports both targeted use cases and enterprise-wide deployment.

To explore what AuroraPrime can deliver for your GVD authoring workflows, book a demo with the AlphaLife Sciences team today.